MedTrace Logo

Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets

NCT05111028 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-11-08

No results posted yet for this study

Summary

Purpose of this study is to compare the reversal responses of 4°C cold stored platelets (CSP) versus 7 day, 22°C room temperature stored platelets (RTP) when given to healthy adult subjects who have received a loading dose of aspirin antiplatelet therapy.

Conditions

  • Reversal of Platelet Aggregation Inhibitors

Interventions

BIOLOGICAL

Autologous Room Temperature stored Platelet transfusion

An autologous transfusion of platelets stored at 22°C for 7 days.

BIOLOGICAL

Autologous Cold Stored Platelet transfusion

An autologous transfusion of platelets stored at 4°C for 7, 14, 21, or 28 days.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Bloodworks

    lead OTHER

Principal Investigators

  • Moritz Stolla, MD, PhD · Bloodworks

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2021-11-30
Completion
2021-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05111028 on ClinicalTrials.gov